WO1999024073A1 - Pharmaceutical compositions containing cyclodextrins and taxoids - Google Patents

Pharmaceutical compositions containing cyclodextrins and taxoids Download PDF

Info

Publication number
WO1999024073A1
WO1999024073A1 PCT/HU1998/000097 HU9800097W WO9924073A1 WO 1999024073 A1 WO1999024073 A1 WO 1999024073A1 HU 9800097 W HU9800097 W HU 9800097W WO 9924073 A1 WO9924073 A1 WO 9924073A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
paclitaxel
docetaxel
taxoid
acetyl
Prior art date
Application number
PCT/HU1998/000097
Other languages
French (fr)
Other versions
WO1999024073B1 (en
Inventor
Joseph M. Géczy
Original Assignee
Thissen Laboratoires S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200000494A priority Critical patent/EA002776B1/en
Priority to CA2309326A priority patent/CA2309326C/en
Priority to DE69839224T priority patent/DE69839224T2/en
Priority to JP2000520158A priority patent/JP3656550B2/en
Priority to KR1020007005076A priority patent/KR100607391B1/en
Priority to IL13599098A priority patent/IL135990A0/en
Priority to BR9814015-9A priority patent/BR9814015A/en
Priority to EP98955818A priority patent/EP1059942B1/en
Application filed by Thissen Laboratoires S.A. filed Critical Thissen Laboratoires S.A.
Priority to NZ504098A priority patent/NZ504098A/en
Priority to AU12538/99A priority patent/AU742036B2/en
Publication of WO1999024073A1 publication Critical patent/WO1999024073A1/en
Publication of WO1999024073B1 publication Critical patent/WO1999024073B1/en
Priority to NO20002165A priority patent/NO329382B1/en
Priority to US11/542,797 priority patent/US7671042B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • This invention relates to new water-soluble solid pharmaceutical compositions and their aqueous solutions for par- enteral use containing taxoids and certain cyclodextrins without noxious solvents and/or detergents . More particularly the invention relates to new water-soluble solid pharmaceutical compositions and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a taxoid such as paclitaxel and docetaxel, optionally in the form of their salts or their polymorphic hydrates or solvates e.g.
  • paclitaxel taxol A
  • docetaxel [N-debenzoyl-N-tert . -butoxycarbonyl) -10- deacetyl-paclitaxel
  • aqueous solvents water of m_ectable quality or an aqueous solution containing a dissolved isotonizer in an amount and concentration effective to isotonize said aqueous solution e.g.
  • HP ⁇ CD hydroxypropyl- ⁇ -cyclodextrin (about 2 to about 8 hydroxypropyl groups per CD-unit)
  • Taxoid is the collective name for paclitaxel and structurally related substances.
  • Paclitaxel is a compound known for its significant anticancer activity acting as a mitotic spindle poison and as a potent inhibitor of cell replication. It also is known to have poor aqueous solubility of about 0.0005 mg/ml at ambient temperature and is reported to be unstable both in solution upon storage and as a consequence of solvoly- sis of its ester linkage leading to loss of cytotoxic activity. It is marketed in solution of a 1 : 1 mixture of ethanol and Cremophor EL (polyhydroxylated castor oil) .
  • Cremophor EL has been implicated in some adverse reactions (hypersensitivity, histamine release) during intravenous treatment and therefore many attempts have been made in the past decade to develop new drug delivery systems.
  • paclitaxel When paclitaxel is formulated as a solution in the organic solvents ethanol and polyethoxylated castor oil, it is administered as a supersaturated oil-in-water emulsion and di- lutes rapidly in the blood, an aqueous environment rich in hy- drophobic domains provided by lipids and proteins. Paclitaxel passes through the hydrophobic environment of the plasma membrane wnile entering and leaving cells by diffusion.
  • docetaxel a semisynthetic taxoid is highly lipophylic and more water soluble than paclitaxel [USP 4814470].
  • Commercially available docetaxel for injection concentrates is a sterile solution of the drug in polysorbate 80, with an accompanying diluent of 13% (w/w) ethanol m water for ⁇ n]ect ⁇ on.
  • the maximal drug concentration which could be used was 0.3 to 0.9 mg/ml . Higher than 0.9 mg/ l had to be avoided because of precipitation problems. Hypersensitivity reactions associated with polysorbate 80 might cause problems with commercially available formulations
  • docetaxel and paclitaxel see PCT WO 95/19994) without details concerning improvement of solubility, stability or toxicity.
  • Such formulations provided a significant increase of aqueous solubility for paclitaxel.
  • precipitation of the drug occured.
  • the basis of the present invention is the recognition that both acetylated- ⁇ -cyclodextrin and hydroxy-propyl- ⁇ - cyclodextrm exhibit a positive effect on the prolongation of the oversaturated state of dissolved paclitaxel and docetaxel preventing premature precipitation without using ethanol as a co-solvent.
  • the aqueous solubility of paclitaxel at room temperature is about 0.5 ⁇ g/ml, therefore the 170 ⁇ g/ml dissolved paclitaxel concentration achieved in 40% acetyl- ⁇ -cyclodextrin solution already means an about 340-fold solubility enhancement.
  • the ' above data however are poor as compared with the known results according to which in an aqueous 40% w/v solution of DIME ⁇ about 800-1000 ⁇ g/ml of paclitaxel was dissolved. Similar poor results were found using HP ⁇ CD as a solubilizer.
  • the object of the present invention is a process for the preparation of pharmaceutical compositions for parenteral use in instantly water-soluble solid state as well as the solutions thereof in aqueous solvents containing acetyl- ⁇ - cyclodextrin or hydroxy-propyl- ⁇ -cyclodextrin (in the following named cyclodextrin ) comprising a) dissolving a taxoid preferably paclitaxel or docetaxel, or their salts or hydrates in ethanol and thereafter performing either of the following steps: i) adding the solid cyclodextrin and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes, dissolving the mixture in an aqueous solvent and lyophilising to obtain a solid or ii)
  • Another preferred embodiment is the use of docetaxel with HP ⁇ CD m the range of 1 : 25 to 1 : 100 weight ratio.
  • any of the following can be used as the aqueous solvent or diluent: water of injectable quality, an aqueous solution of an isotonizing additive such as sodium chloride, glucose, mannitol, dextrose.
  • the latter solutions have to contain said ingredients m an amount to ef- fectively isotonize the aqueous solution under the conditions hereunder.
  • concentrations known to be suitable for isotonizers in pharmaceutical solutions might be changed somewhat by the presence of the cyclodextnns and the taxoids employed.
  • concentrations in the mag- nitude of about 0.9 % w/v of sodium chloride, or about 5% w/v of glucose have to be optimised for the specific composition depending on the taxoid employed and on the amount and quality of the CD used.
  • compositions containing as active ingredients any of the products whenever prepared according to the processes of the invention.
  • a still further object of the present invention are water-soluble solid pharmaceutical compositions and their solutions m aqueous solvents, said compositions containing a) as an active ingredient a finely dispersed large surface area taxoid such as paclitaxel or do- cetaxel, optionally m the form of their salts or their polymorphic hydrates or solvates e.g. formed with ethanol and b) finely dispersed, large surface area acetyl- ⁇ - cyclodextrin or hydroxy-propyl- ⁇ -cyclodextrm ( cyclodextrin )
  • the weight ratio of said taxoid : said cyclodextrin ranging between 1 : 25 and 1 : 250; c) and optionally other water-soluble auxiliary materials usual m pharmaceuticals for parenteral purposes .
  • compositions according to the invention contain as the active ingredient paclitaxel and as the cyclodextrin acetyl- ⁇ -cyclodextrin in a 1 : 100 to 1 :
  • compositions are com ⁇ binations of docetaxel and hydroxy-propyl- ⁇ -cyclodext ⁇ n m a 1 : 25 to 1 : 100 weight ratio.
  • Further objects of the present invention are meth- ods for prevention of self-aggregation and premature precipitation of a taxoid such as paclitaxel and docetaxel and their salts, solvates and hydrates in aqueous solu ⁇ tions and for prolongation of the oversaturated dissolved state of the drugs by using the taxoids the form of pharmaceutical compositions according to the present in ⁇ vention as described above in detail.
  • a taxoid such as paclitaxel and docetaxel and their salts, solvates and hydrates in aqueous solu ⁇ tions and for prolongation of the oversaturated dissolved state of the drugs by using the taxoids the form of pharmaceutical compositions according to the present in ⁇ vention as described above in detail.
  • Yet another object of the present invention is the method of treatment of unwanted cell proliferation by utilising effective amounts of pharmaceutical compositions according to the invention as described above in detail.
  • the ready-to-use paclitaxel solutions remain physically stable for a reasonable period of time.
  • Intravenous treatment generally requires that solutions be used which are physically stable for at least 6 hours.
  • the thus reconstituted solutions are stable for at least 6 to 8 hours.
  • solutions of the combinations paclitaxel /Ac ⁇ CD as well as do- cetaxel/Ac ⁇ CD or HP ⁇ CD more than 24 hours of physical stabilities were measured.
  • a parenteral dosage form containing the pharmaceutical composition containing the pharmaceutical composition.
  • Dosage units of 100 mg taxoid may be prepared in lyophi- lised form. These are diluted to give the ready to use dosage solutions applicable e.g. for intravenous treatment.
  • several 100 mg units may be applied so as to reach the effective dose corresponding to the desired amount expressed generally in mg/m 2 body surface.
  • the recommended dose of paclitaxel ranging from 135 to 250 mg/m 2 body surface can be reached.
  • the drug can be used effectively e.g.
  • paclitaxel 3 mg are added to 500 mg of acetyl- ⁇ -cyclodextrm powder ( freeze-dried from aqueous solution) . This mixture is kept under vacuum for 18 hours over phosphorous pentoxide to remove the ethanol.
  • Example 1.2 Preparation of a paclitaxel formulation of 0.6 mg/ml nominal paclitaxel concentration
  • amorphised acetyl- ⁇ -cyclodextrin are wetted with 3 ml of a paclitaxel solution of 10 mg/ml paclitaxel concentration (corresponding to 30 mg of paclitaxel) .
  • a paclitaxel solution of 10 mg/ml paclitaxel concentration (corresponding to 30 mg of paclitaxel) .
  • a 5% dextrose solution are added to the wet mixture and the composition is shaken until a clear solution is obtained.
  • the dissolved paclitaxel concentration solu- tion amounts to 0.55 ⁇ 0.05 mg/ml determined oy HPLC after filtration of the solution through a 0.2 ⁇ m me ⁇ uorane filter.
  • the solution can be stored at room temperature under normal light conditions in glass containers for at least 6 hours without noticeable opalescence and/or particle formation.
  • the re-anaJysis of the dissolved paclitaxel after 6 hours of storage by HPLC shows that no
  • Example 1.3 Preparation of a paclitaxel formulation of ⁇ 0.3 mg/ml nominal paclitaxel concentration
  • a paclitaxel solution of 10 mg/ml paclitaxel concentration (corresponding to 30 mg of paclitaxel) .
  • 100 ml of a 5% dextrose solu- tion aie added and the mixture is shaken until a clear solution is obtained.
  • the dissolved paclitaxel concentration in this solution amounts to 0.27 ⁇ 0.03 mg/ml, determined by HPLC after filtration of the solution across a 0.2 ⁇ m membrane filter.
  • the solution can be stored at room temperature under nor- mal light conditions m glass containers for at least 12 hours without noticeable opalescence and/or particle formation.
  • the HPLC re-analysis of the dissolved paclitaxel after 12 hours of storage snows that no decrease of dissolved paclitaxel concentration took place during 12 hours.
  • Example 1.4. Preparation of docetaxel formulation of 0.5 and 1 mg/ml nominal docetaxel concentration
  • amorphised acetyl- ⁇ -cyclodextrin 100 mg are wetted with 0.1 ml of a docetaxel solution of 20 mg/ml docetaxel concentration (this corresponds to 2 mg of docetaxel) .
  • a docetaxel solution 20 mg/ml docetaxel concentration (this corresponds to 2 mg of docetaxel) .
  • To samples of this wet solid mixture immediately 1 or 2 ml of a 5% w/v aqueous dextrose solution are added and the mixture is shaken until a clear solution is obtained.
  • the dissolved docetaxel concentrations in solution according to Example 1.4. amount to 1 and 0.5 mg/ml respectively.
  • the solutions can be stored at room temperature under normal light conditions in glass containers for at least 24 hours without noticeable opalescence and/or particle formation.
  • the composition of both solutions referred to 20 mg docetaxel dosage unit is as fol- lows:
  • Example 1.5 Preparation of a docetaxel formulation of 0.75 mg/ml nominal docetaxel concentration using hydroxypro- pyl- ⁇ -cyclodextrin (HP ⁇ CD)
  • Example 1.6 Preparation of binary paclitaxel /acetyl- ⁇ -cyclodextrin co-lyophilisate.
  • This lyophilisate can easily be reconstituted into the original volume solution by way of adding of 50 ml of an 5% aqueous glucose solution.
  • the result is a clear solution with 0.6 mg/ml paclitaxel concentration.
  • the reconstituted solution is stored at room temperature under normal conditions m glass containers.
  • the paclitaxel concentration was assayed using the HPLC method after filtration of the test solutions through a 0.2 ⁇ m membrane.
  • the paclitaxel content after preparation 0.513 ⁇ 0.07 mg/mL* after 25 hours of storage 0.556 ⁇ 0.01 mg/ml (* The difference between nominal and measured paclitaxel concentration is due to the volume expansion of the bulk lyophilisate. )
  • Example 1.7 Preparation of binary docetaxel/acetyl- ⁇ - cyclodextrin co-lyophilisate . 10 mg of docetaxel dissolved m 0.5 ml of ethanol are added to 400 mg of amorphised acetyl ⁇ -cyclodextrin. The wet powder is dissolved 8 ml of distilled water resulting in a clear solution with 1.25 mg/ml nominal docetaxel concentration. This solution is frozen quickly m dry-ice and freeze dried to obtain a white lyophilisate with 2.25 ⁇ 0.1% docetaxel content.
  • Example 1.8. Preparation of paclitaxel /acetyl- ⁇ - cyclodextrin /glucose co-lyophilisate
  • paclitaxel 30 mg are dissolved in 3 ml of ethanol and the solution is added to 5.0 g of amorphised acetyl- ⁇ - cyclodextrin.
  • To the wet powder further 2 ml of ethanol are added and the powder is then dissolved in 50 ml of a 5% aqueous glucose solution. This solution is frozen in dry-ice and freeze-dried to give a white lyophilisate with 0.42 ⁇ 0.01 % paclitaxel content.
  • This lyophilisate can easily be reconstituted into the original volume on addition of 50 ml of distilled water.
  • the result is a clear solution with 0.6 mg/ml nominal paclitaxel concentration .
  • the reconstituted solutions are stored at room temperature under normal conditions in closed glass containers.
  • the paclitaxel concentration during storage is measured using the HPLC method after filtration of the test solutions.
  • Paclitaxel content found: immediately on preparation: 0.530 ⁇ 0.08 mg/mL* after 25 hours of storage 0.541 ⁇ '0.05 mg/ml (* The difference between nominal and measured paclitaxel concentration is due to the volume expansion of the bulk lyophilisate . )
  • Example 1.9 Preparation of docetaxel/acetyl- ⁇ - cyclodextrin/glucose co-lyophilisate 8 mg of docetaxel dissolved in 0.4 ml of ethanol are added to 400 mg of amorphised acetyl- ⁇ -cyclodextrin. The wet powder is then dissolved in 8 ml of a 5% w/v aqueous glucose solution. This results in a clear solution with 1 mg/ml nominal docetaxel concentration which is frozen m dry-ice and freeze-d ⁇ ed, to give a white lyophilisate with 1% docetaxel content.
  • 100 mg of ethanol free solid lyophilisate can easily be reconstituted in 1, 2 or 4 ml of distilled water giving clear solutions of 1, 0.5 or 0.25 mg/ml nominal docetaxel concentrations, respectively.
  • Table 6 physical stability of do- cetaxel solutions during 21 hours of storage at room temperature in closed glass containers are summarised by determination of the dissolved docetaxel concentration by HPLC at different nominal concentrations.
  • Example I.10 Preparation of binary do- cetaxel/hydroxypropyl- ⁇ -cyclodext ⁇ n (HP ⁇ CD) co-lyophilisate .
  • 6 mg of docetaxel dissolved in 0.3 ml of ethanol are added to 300 mg of HP ⁇ CD.
  • the wet powder is dissolved m 6 ml of distilled water resulting m a clear solution with 1 mg/ml nominal docetaxel concentration.
  • This solution is frozen quickly in dry-ice and freeze dried, to obtain a white lyophilisate with 2_ w/w docetaxel content.
  • 50 mg of the solid lyophilisate can easily be dissolved in 1 or 2 ml of a 5% w/v aqueous glucose solutions giving a clear solution of 0.97 and 0.59 mg/ml docetaxel content respectively, as determined by HPLC.
  • the reconstituted solutions are stored at room tempera- ture under normal conditions in glass containers. After 21 hours of storage 0.95 ⁇ 0.05 and 0.49 ⁇ 0.005 mg/ml docetaxel concentrations are assayed by HPLC.
  • Example I.11 Prolongation of the oversaturated dissolved state of the paclitaxel by way of co-evaporation 30 mg of Paclitaxel are dissolved in 6 ml of ethanol and the solution is mixed thoroughly with 5 g of acetyl- ⁇ - cyclodextrin. Additional 3 ml of ethanol are added and the mixture is stirred for 5 minutes at room temperature. The ethanol content of the mixture is then removed in nitrogen stream using a rotatory evaporator in vacuum. The resulting white solid is then dissolved in 5 ml of deionised water resulting in a slightly opalescent solution that is immediately frozen with dry-ice and freeze-dried. The resulting lyophilisate is an instantly soluble amorphous powder.
  • Example 1.12 Parenteral composition for intravenous use 100 mg of paclitaxel dissolved in 10 ml of ethanol are added to 15.0 g of amorphised large surface area acetyl- ⁇ - cyclodextrin. To the wet powder further 10 ml of ethanol are added and the powder is dissolved in 80 ml of distilled water resulting in a clear solution with 1.25 mg/ml nominal pacli- taxel concentration. This solution is frozen quickly in dry- ice and freeze-dried to yield a white lyophilisate with 0.7 ⁇ 0.05 %w paclitaxel content.
  • This lyophilisate can easily be reconstituted to 100 ml using a 5% w/v aqueous dextrose solution.
  • a clear solution with 1.0 mg/ml paclitaxel concentration is obtained ready to use for intravenous application.
  • Heart rate (beats/minute)
  • Electrodiagram (lead H) Electrical status of the myocardium
  • Anaesthesia was induced by I.V. injection of sodium thio- pentone and maintained i.v. by a mixture of -chloralose and pentobarbitone sodium given as required. Body temperature was maintained.
  • the trachea was cannulated and the canule connected to a pneumotach screen to allow measurement of tidal volume (ml) and the derived parameters of respiration rate (br/min) and minute volume (ml) .
  • Catheters were introduced into the right femoral artery and a cephalic vein to facilitate measurements of blood pressure and the administration of vehicle, test sub- stances and anaesthetic respectively.
  • the femoral artery was connected to a hepar /salme filled pressure transducer, coupled to a Grass 7E polygraph.
  • Heart rate was derived elec- tronically from the blood pressure signal.
  • An ultrasonic flow probe was positioned around the left femoral artery and connected to a blood flow meter coupled to the Grass polygraph to record femoral blood flow (ml/mm) .
  • a catheter was introduced into the left carotid artery and advanced into the left ventricle to facilitate the measurement of the left ventricular systolic pressure (LVSP) .
  • the catheter was connected to a heparm/salme-filled pressure transducer and the LVSP signal was displayed on the Grass polygraph.
  • Subcutaneous needle electrodes were inserted in the appropriate limbs m order to monitor the electrocardiogram which was displayed on the Grass polygraph.
  • Various signals were transferred from the Grass polygraph to a computer and the captured data were analysed and displayed.
  • the vehicle was administered i.v. at a dose volume of 7.0 ml/kG over a pe- nod of 15 minutes. 45 minutes later and a minimum of 45 minutes intervals thereafter doses of the drugs were administered i.v. at a dose volume of 7.0 ml/kG again over 15 minutes each. The parameters were monitored for a least 45 minutes from the start of infusion. All doses were administered using a KdS model 200 infusion pump.
  • Cremophor ELP ethanol 1:1 was discontinued because of death of the animals.
  • Intravenous administration of Cremophor ELP ethanol at both dose levels (corresponding to the doses used with 6 and 60 mg/m 2 paclitaxel respectively) induced an anaphylactic type response: immediate decrease in arterial blood pressure, heart rate, left ventricular systolic pressure and left ventricular dp/dt maximum of similar magnitude in both animals. Little or no recovery in any cardiovascular parameter was observed post-dose.
  • FIGURES To illustrate an important parameter of the results the effect on arterial blood pressure following i.v. administration in the anaesthetised beagle dog is shown in Figures 1 to 6: Arterial blood pressure (mmHg) versus time (minutes):

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to water-soluble solid pharmaceutical compositions and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a finely dispersed large surface area amorphous preferably lyophilized taxoid such as paclitaxel or docetaxel, their salts or their polymorphic hydrates or solvates such as solvates formed with ethanol and b) finely dispersed large surface area amorphous preferably lyophilized acetyl-η-cyclodextrin or hydroxy-propyl-β-cyclodextrin (cyclodextrin) whereby the weight ratio of said taxoid : said cyclodextrin ranges between 1 : 25 and 1 : 400; c) and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parental purposes.

Description

PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINS AND TAXOIDS. This invention relates to new water-soluble solid pharmaceutical compositions and their aqueous solutions for par- enteral use containing taxoids and certain cyclodextrins without noxious solvents and/or detergents . More particularly the invention relates to new water-soluble solid pharmaceutical compositions and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a taxoid such as paclitaxel and docetaxel, optionally in the form of their salts or their polymorphic hydrates or solvates e.g. solvates formed with ethanol; and b) a large surface area acetyl-γ-cyclodextnn or hy- droxy-propyl-β-cyclodextπn ( in the following the cyclodextrin)
- whereby the weight ratio of said taxoid to said cy- clodextnn ranges between 1 : 25 and 1 : 250; c) and optionally other water-soluble auxiliary materials usual m pharmaceuticals for parenteral purposes.
The invention also relates to the preparation and use of said injectable pharmaceutical compositions. The following definitions are used throughout the specification and claims: paclitaxel = taxol A; docetaxel = [N-debenzoyl-N-tert . -butoxycarbonyl) -10- deacetyl-paclitaxel ; "aqueous solvents" = water of m_ectable quality or an aqueous solution containing a dissolved isotonizer in an amount and concentration effective to isotonize said aqueous solution e.g. sodium chloride, glucose; "amorphα sed" = showing amorphous structure against X-rays; CD = cyclodextrin γ-cyclodextrin = cyclomaltooctaose β-cyclodextrin = cyclomaltoheptaose Ac γCD = acetyl- γ-cyclodextrin
HPβCD = hydroxypropyl-β-cyclodextrin (about 2 to about 8 hydroxypropyl groups per CD-unit)
DIMEβ = heptakis-2, 6-di-0-methyl-β-cyclodextrin
Taxoid is the collective name for paclitaxel and structurally related substances. Paclitaxel is a compound known for its significant anticancer activity acting as a mitotic spindle poison and as a potent inhibitor of cell replication. It also is known to have poor aqueous solubility of about 0.0005 mg/ml at ambient temperature and is reported to be unstable both in solution upon storage and as a consequence of solvoly- sis of its ester linkage leading to loss of cytotoxic activity. It is marketed in solution of a 1 : 1 mixture of ethanol and Cremophor EL (polyhydroxylated castor oil) .
Cremophor EL has been implicated in some adverse reactions (hypersensitivity, histamine release) during intravenous treatment and therefore many attempts have been made in the past decade to develop new drug delivery systems.
When paclitaxel is formulated as a solution in the organic solvents ethanol and polyethoxylated castor oil, it is administered as a supersaturated oil-in-water emulsion and di- lutes rapidly in the blood, an aqueous environment rich in hy- drophobic domains provided by lipids and proteins. Paclitaxel passes through the hydrophobic environment of the plasma membrane wnile entering and leaving cells by diffusion.
The propensity of paclitaxel to undergo solvent- and concentration-dependent self-aggregation has hampered efforts to formulate this poorly soluble drug in pharmaceutically acceptable excipients for clinical administration.
It is also known that docetaxel, a semisynthetic taxoid is highly lipophylic and more water soluble than paclitaxel [USP 4814470]. Commercially available docetaxel for injection concentrates is a sterile solution of the drug in polysorbate 80, with an accompanying diluent of 13% (w/w) ethanol m water for ιn]ectιon. The maximal drug concentration which could be used was 0.3 to 0.9 mg/ml . Higher than 0.9 mg/ l had to be avoided because of precipitation problems. Hypersensitivity reactions associated with polysorbate 80 might cause problems with commercially available formulations
A wide range of approaches has been taken m formulation, including vehicles with hydrophobic characteristics. In most vehicles the taxoid is formulated m the millimolar concen- tration range which is comparable to the concentrations at which the taxoid was observed to self-aggregate resulting n precipitation.
Based on the interaction between the taxoid and cyclodex- tπns several further suggestions were made. Studying the thin-layer chromatographic mobility of the taxoid in presence of cyclodextπns (Int. J. Pharm. 1994. 108. 64-75.) it was first concluded that the interaction between taxoid and cyclodextrin was very weak. Later (AU-P-35544/93; 645.927) a modest enhancement of the solubility of the taxoid was found using unsubstituted cyclodextnns and enzyme-modifled branched-β-cyclodextnns .
Aqueous parenteral solutions of sparingly soluble drugs in water combined with cyclodextnns were suggested to mini¬ mize drug precipitation at in ection sites or organs following parenteral application (USP 5 024 998). Solubility enhancement was hereby observed using high (around 50% w/v) CD concentration and solid complexes were obtained with some products from these concentrates emphasizing that below a 20% w/v CD concentration precipitation might occur. Among the tremendous amount of drugs enlisted m this specification there is no word concerning taxoids nor acetyl-γCD.
Using an aqueous solution of methylated β-cyclodextπns as effective paclitaxel solubility enhancers (PCT WO 94/ 26728) and combining of methylated β-cyclodextπn and ethanol for preparation of 1 to 4 mg/ml paclitaxel solutions (EP
788373) represented further improvements. These taxoid con- centrates did not precipitate on dilution up to a certain limit and avoided use of toxic detergents. Also the use of 2, 6-dι-O-methyl-β-cyclodextrm was suggested as a more effective solubilizer of paclitaxel (EPA 0639380) and detailed re- suits on its solubilizmg potency were published (J. Pharm. Sci. 84. 10. 1223-1230; 1995). However some concern was expressed concerning the use of methylated β-cyclodextrms m m_ectables because of their surfactant properties, their affinity to cholesterol and other cell-membrane lipid components already at low concentration and doses.
Some studies were published on the use of cyclodextnns along ith water-soluble drugs to achieve less ulceration compared in the same formulation of cytotoxic compounds when ex- travasated (WO 95/06485) . Though paclitaxel is not water- soluble, this patent specification also includes an example of "Taxol" m 50% ethanol solution to illustrate this effect adding "HPCD" . The results show that HPCD exerted a protective effect on skin when Taxol was deposited into an mtradermal site, resulting m the reduction m lesion size. Thio-branched cyclodextnns were disclosed for solubilizmg anticancer taxoids (e.g. docetaxel and paclitaxel see PCT WO 95/19994) without details concerning improvement of solubility, stability or toxicity. Such formulations provided a significant increase of aqueous solubility for paclitaxel. However on dilution for parenteral application (0.3 to 1.2 mg/ml) precipitation of the drug occured.
It was the aim of the present invention to further improve both solubility of taxoids in mjectable formulations and stability of taxoid drug systems for parenteral admini- stration while possibly decreasing toxicity of accompanying materials used for formulation purposes.
The basis of the present invention is the recognition that both acetylated- γ-cyclodextrin and hydroxy-propyl-β- cyclodextrm exhibit a positive effect on the prolongation of the oversaturated state of dissolved paclitaxel and docetaxel preventing premature precipitation without using ethanol as a co-solvent. This was a surprising fact it being known that γ- cyclodextrin and its hydroxypropylated derivatives - which are known to possess the largest size cavities among the CDs - have been previously disclosed to be less suitable for pacli- taxel solubilization and complexation (Int. J. Pharm. 133. 191-201.1996). This was confirmed by our studies registering the equilibrium solubility of paclitaxel in function of the concentration of aqueous solutions of chemically modified γ- cyclodextrins whereby no practically useful solubilizing ef- feet was found though high cyclodextrin-concentrations were used. See Table 1: Solubility of paclitaxel as a function of acetyl- γ -cyclodextrin concentration) .
Table 1
Figure imgf000007_0001
The aqueous solubility of paclitaxel at room temperature is about 0.5 μg/ml, therefore the 170 μg/ml dissolved paclitaxel concentration achieved in 40% acetyl- γ -cyclodextrin solution already means an about 340-fold solubility enhancement. The' above data however are poor as compared with the known results according to which in an aqueous 40% w/v solution of DIMEβ about 800-1000 μg/ml of paclitaxel was dissolved. Similar poor results were found using HPβCD as a solubilizer. This value is far from the desirable value corresponding to the therapeutic dose of paclitaxel and the use of such dosage form would require administration of more than 70 grams of cyclodextrin with the paclitaxel dose unit of 30 mg. The object of the present invention is a process for the preparation of pharmaceutical compositions for parenteral use in instantly water-soluble solid state as well as the solutions thereof in aqueous solvents containing acetyl- γ - cyclodextrin or hydroxy-propyl- β-cyclodextrin (in the following named cyclodextrin ) comprising a) dissolving a taxoid preferably paclitaxel or docetaxel, or their salts or hydrates in ethanol and thereafter performing either of the following steps: i) adding the solid cyclodextrin and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes, dissolving the mixture in an aqueous solvent and lyophilising to obtain a solid or ii) adding the solid, large surface area amorphous (preferably lyophilised) cyclodextrin and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes, evaporating the solvent and drying to obtain a solid or iii) admixing the solution with solid large surface area amorphous preferably freeze-dried cyclodex-- trin (and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes), thereafter dissolving with an aqueous sol- vent optionally in the presence of an effective amount of an isotonizing additive to obtain a solution; containing a) as an active ingredient the said taxoid and b) the said cyclodextrin and c) optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes whereby the weight ratio of taxoid : cyclodextrin is between the range 1 : 25 to 1 : 400; and optionally b) when steps 1) or 11) were used dissolving the solid m an aqueous solvent to obtain a parenteral solution ready for direct medical treatment . According to the invention the taxoid paclitaxel is used in its hydrated polymorphic form or m its sol- vated form such as the ethanol solvate.
It is a preferred embodiment of the invention to use as the active ingredient paclitaxel together with acetyl- γ-cyclodextrin in a 1 : 100 to 1 : 250 weight ratio. Another preferred embodiment is the use of docetaxel with HPβCD m the range of 1 : 25 to 1 : 100 weight ratio.
When carrying out the process according to the m- vention any of the following can be used as the aqueous solvent or diluent: water of injectable quality, an aqueous solution of an isotonizing additive such as sodium chloride, glucose, mannitol, dextrose. The latter solutions have to contain said ingredients m an amount to ef- fectively isotonize the aqueous solution under the conditions hereunder. Thus the concentrations known to be suitable for isotonizers in pharmaceutical solutions might be changed somewhat by the presence of the cyclodextnns and the taxoids employed. Thus the concentrations in the mag- nitude of about 0.9 % w/v of sodium chloride, or about 5% w/v of glucose have to be optimised for the specific composition depending on the taxoid employed and on the amount and quality of the CD used.
Further objects of the present invention are the pharmaceutical compositions containing as active ingredients any of the products whenever prepared according to the processes of the invention.
A still further object of the present invention are water-soluble solid pharmaceutical compositions and their solutions m aqueous solvents, said compositions containing a) as an active ingredient a finely dispersed large surface area taxoid such as paclitaxel or do- cetaxel, optionally m the form of their salts or their polymorphic hydrates or solvates e.g. formed with ethanol and b) finely dispersed, large surface area acetyl- γ - cyclodextrin or hydroxy-propyl-β-cyclodextrm ( cyclodextrin )
the weight ratio of said taxoid : said cyclodextrin ranging between 1 : 25 and 1 : 250; c) and optionally other water-soluble auxiliary materials usual m pharmaceuticals for parenteral purposes .
Preferred compositions according to the invention contain as the active ingredient paclitaxel and as the cyclodextrin acetyl- γ -cyclodextrin in a 1 : 100 to 1 :
250 weight ratio. Further preferred compositions are com¬ binations of docetaxel and hydroxy-propyl-β-cyclodextπn m a 1 : 25 to 1 : 100 weight ratio.
Further objects of the present invention are meth- ods for prevention of self-aggregation and premature precipitation of a taxoid such as paclitaxel and docetaxel and their salts, solvates and hydrates in aqueous solu¬ tions and for prolongation of the oversaturated dissolved state of the drugs by using the taxoids the form of pharmaceutical compositions according to the present in¬ vention as described above in detail.
Yet another object of the present invention is the method of treatment of unwanted cell proliferation by utilising effective amounts of pharmaceutical compositions according to the invention as described above in detail. The ready-to-use paclitaxel solutions remain physically stable for a reasonable period of time. Intravenous treatment generally requires that solutions be used which are physically stable for at least 6 hours. When dissolving the compounds according to the present invention in aqueous solutions the thus reconstituted solutions are stable for at least 6 to 8 hours. In the case of solutions of the combinations paclitaxel /Ac γ CD as well as do- cetaxel/Acγ CD or HPβCD more than 24 hours of physical stabilities were measured.
According to the method it is provided to administer to a patient in need of such treatment a parenteral dosage form containing the pharmaceutical composition. Dosage units of 100 mg taxoid may be prepared in lyophi- lised form. These are diluted to give the ready to use dosage solutions applicable e.g. for intravenous treatment. Depending on the required treatment applicable in the specific needs of the patient several 100 mg units may be applied so as to reach the effective dose corresponding to the desired amount expressed generally in mg/m2 body surface. Thus e.g. the recommended dose of paclitaxel ranging from 135 to 250 mg/m2 body surface can be reached. The drug can be used effectively e.g. by way of intrave- nous, intraperitoneal, intramuscular administration depending on the type of cancer to be treated and the taxoid and cyclodextrin selected for use. Improved results of treatment as compared with known therapies can be achieved due to the considerably decreased toxicity of the dosage form as compared with the toxicity of the vehicles contained in the known compositions used to date. It is also no more necessary to subject the patient to premedication against hypersensitivity and other unwanted side-effects using steroids, antihistamines and ^-receptor antagonists before paclitaxel or docetaxel administration to prevent severe hypersensitivity reactions. Details of the invention are given m the Examples below by way of illustration and without the intention to limit the scope of protection. I . PREPARATION OF FORMULATIONS Example I.I.: Preparation of reconstitutable, solid paclitaxel /acetyl- γ-cyclodextrm combinations by drying.
3 mg of paclitaxel (dissolved m 0.3 ml of ethanol) are added to 500 mg of acetyl- γ-cyclodextrm powder ( freeze-dried from aqueous solution) . This mixture is kept under vacuum for 18 hours over phosphorous pentoxide to remove the ethanol.
Portions of this ethanol-free powder combination are dissolved in 5, 4, 3 and 2 ml of 5% aqueous glucose solutions respectively. The physical stability of these reconstituted solutions is shown m Table 2.
TABLE 2
Added ml of 5% glucose solution 5 ml 4 ml 3 ml 2 ml final paclitaxel mg/ml 0.6 0.75 1.0 1.5 final AcγCD mg/ml _ 100 125 167 250 stability evaluated >120 > 48 > 48 > 48 visually hours. after 72 hours precipitation occurred dissolved paclitaxel mg/ml (HPLC) 0.576
This experiment has been repeated with lower amounts of acetyl- γ-cyclodextrm. 3 mg of paclitaxel (dissolved m 0.3 ml of ethanol) is added to 450 mg, 400 mg or 350 mg of freeze- dried acetyl- γ -cyclodextrin samples, thereafter it is kept under vacuum for 18 hours over phosphorous pentoxide to remove the ethanol. These combinations have been dissolved 5, 4, 3 and 2 ml each of an 5 aqueous glucose solution. In Table 3, 4, 5 the composition as well as the physical stability of these reconstituted paclitaxel solutions prepared according to Example I.l using different amounts of acetyl- γ-cyclodextrm are summarised.
TABLE 3
Added ml of 5% glucose solution
5 ml 4 ml 3 ml 2 ml final paclitaxel mg/ml 0 6 0 75 1 0 1 5 final acetyl- γ- cyclodextrin 90 112 5 150 225 stability, evaluated visually in hours opalescent solution > 48 > 48 > 48
TABLE 4
Added ml of 5% glucose solution
5 ml 4 ml 3 ml 2 ml final paclitaxel mg/ml 0 6 0 75 1 0 1 5 final acetyl γCD mg/ml 80 100 133 200 stability, evaluated visually in < 4 > 24 hours slight opalescence > > clear solution dissolved paclitaxel mg/ml on prep 0 41 1 26 after 22 hours . 0 42 • . 1 25
TABLE 5
Added ml of 5% glucose solution
5 ml 4 ml 3 ml 2 ml final paclitaxel mg/ml 0 6 0 75 1 0 1 5 final Ac γCD 70 86 1 17 , 1 75 stability, evaluated visually increasing opalincreasing opal- > 24 in hours escence escence almost clear solu
Figure imgf000013_0001
dissolved paclitaxel mg/ml (HPLC) at prep . 1.16 after 22 hours . 1.17
Example 1.2. : Preparation of a paclitaxel formulation of 0.6 mg/ml nominal paclitaxel concentration
6.5 g of amorphised acetyl- γ -cyclodextrin are wetted with 3 ml of a paclitaxel solution of 10 mg/ml paclitaxel concentration (corresponding to 30 mg of paclitaxel) . Immediately 50 ml of a 5% dextrose solution are added to the wet mixture and the composition is shaken until a clear solution is obtained. The dissolved paclitaxel concentration solu- tion amounts to 0.55 ± 0.05 mg/ml determined oy HPLC after filtration of the solution through a 0.2 μm meπuorane filter. The solution can be stored at room temperature under normal light conditions in glass containers for at least 6 hours without noticeable opalescence and/or particle formation. The re-anaJysis of the dissolved paclitaxel after 6 hours of storage by HPLC shows that no decrease of dissolved paclitaxel concentration took place.
Example 1.3. : Preparation of a paclitaxel formulation of ~ 0.3 mg/ml nominal paclitaxel concentration
6.5 g of previously amorphised acetyl- γ-cyclodextrm is wetted with 3 ml of a paclitaxel solution of 10 mg/ml paclitaxel concentration (corresponding to 30 mg of paclitaxel) . To this wet mixture immediately 100 ml of a 5% dextrose solu- tion aie added and the mixture is shaken until a clear solution is obtained. The dissolved paclitaxel concentration in this solution amounts to 0.27 ± 0.03 mg/ml, determined by HPLC after filtration of the solution across a 0.2 μm membrane filter. The solution can be stored at room temperature under nor- mal light conditions m glass containers for at least 12 hours without noticeable opalescence and/or particle formation. The HPLC re-analysis of the dissolved paclitaxel after 12 hours of storage snows that no decrease of dissolved paclitaxel concentration took place during 12 hours. Example 1.4. : Preparation of docetaxel formulation of 0.5 and 1 mg/ml nominal docetaxel concentration
100 mg of amorphised acetyl- γ -cyclodextrin are wetted with 0.1 ml of a docetaxel solution of 20 mg/ml docetaxel concentration (this corresponds to 2 mg of docetaxel) . To samples of this wet solid mixture immediately 1 or 2 ml of a 5% w/v aqueous dextrose solution are added and the mixture is shaken until a clear solution is obtained. The dissolved docetaxel concentrations in solution according to Example 1.4. amount to 1 and 0.5 mg/ml respectively. The solutions can be stored at room temperature under normal light conditions in glass containers for at least 24 hours without noticeable opalescence and/or particle formation. The composition of both solutions referred to 20 mg docetaxel dosage unit is as fol- lows:
- 1000 mg Ac γCD
20 mg 'docetaxel
1 ml ethanol 20 ml or 40 ml 5% dextrose
Example 1.5. : Preparation of a docetaxel formulation of 0.75 mg/ml nominal docetaxel concentration using hydroxypro- pyl-β-cyclodextrin (HPβCD)
200 mg of HPβCD is wetted with 0.15 ml of a docetaxel so- lution of 10 mg/ml docetaxel concentration (This corresponds to 1.5 mg of docetaxel) . To this wet mixture immediately 2. ml of a 5% aqueous dextrose solution are added and the mixture is shaken until a clear solution is obtained. The dissolved docetaxel concentration in solution according to Example 1.5. amounts to 0.75 mg/ml. The solutions can be stored at room temperature under normal light conditions in glass containers for at least 24 hours without noticeable opalescence and/or particle formation. The composition of solutions referred to 20 mg docetaxel dosage unit is as follows: - 2670 mg HPβCD
20 mg docetaxel 2 ml ethanol 27 ml 5% dextrose
Example 1.6. : Preparation of binary paclitaxel /acetyl- γ -cyclodextrin co-lyophilisate.
30 mg of paclitaxel dissolved m 3 ml of ethanol is added tc 5.0 g of amorphised acetyl- γ-cyclodextrm. To the wet powder further 2 ml of ethanol are added and the powder is dissolved m 50 ml of distilled water resulting a clear so- lution with 0.6 mg/m nominal paclitaxel concentration. This solution is frozen quickly m dry-ice and freeze dried to obtain a white lyophilisate with 0.6 ± 0.05 % / w paclitaxel content .
This lyophilisate can easily be reconstituted into the original volume solution by way of adding of 50 ml of an 5% aqueous glucose solution. The result is a clear solution with 0.6 mg/ml paclitaxel concentration.
The reconstituted solution is stored at room temperature under normal conditions m glass containers. The paclitaxel concentration was assayed using the HPLC method after filtration of the test solutions through a 0.2 μm membrane. The paclitaxel content after preparation: 0.513 ± 0.07 mg/mL* after 25 hours of storage 0.556 ± 0.01 mg/ml (* The difference between nominal and measured paclitaxel concentration is due to the volume expansion of the bulk lyophilisate. )
Example 1.7. : Preparation of binary docetaxel/acetyl- γ - cyclodextrin co-lyophilisate . 10 mg of docetaxel dissolved m 0.5 ml of ethanol are added to 400 mg of amorphised acetyl γ -cyclodextrin. The wet powder is dissolved 8 ml of distilled water resulting in a clear solution with 1.25 mg/ml nominal docetaxel concentration. This solution is frozen quickly m dry-ice and freeze dried to obtain a white lyophilisate with 2.25 ± 0.1% docetaxel content. 50 mg of the solid lyophilisate can easily be dissolved in 1 ml of a 5% aqueous glucose solution resulting in a clear solution of 1.13 mg/ml docetaxel content (determined by HPLC). The reconstituted solution can be stored at room tempera- ture under normal conditions in a glass container. After 21 hours of storage 1.15 ± 0.02 mg/ml docetaxel concentration is assayed using the HPLC method. Even after 72 hours of storage there is no visually observable opalescence or solid particle formation in the solution. Example 1.8. : Preparation of paclitaxel /acetyl- γ - cyclodextrin /glucose co-lyophilisate
30 mg of paclitaxel are dissolved in 3 ml of ethanol and the solution is added to 5.0 g of amorphised acetyl- γ- cyclodextrin. To the wet powder further 2 ml of ethanol are added and the powder is then dissolved in 50 ml of a 5% aqueous glucose solution. This solution is frozen in dry-ice and freeze-dried to give a white lyophilisate with 0.42 ± 0.01 % paclitaxel content.
This lyophilisate can easily be reconstituted into the original volume on addition of 50 ml of distilled water. The result is a clear solution with 0.6 mg/ml nominal paclitaxel concentration .
The reconstituted solutions are stored at room temperature under normal conditions in closed glass containers. The paclitaxel concentration during storage is measured using the HPLC method after filtration of the test solutions. Paclitaxel content found: immediately on preparation: 0.530 ± 0.08 mg/mL* after 25 hours of storage 0.541 ±'0.05 mg/ml (* The difference between nominal and measured paclitaxel concentration is due to the volume expansion of the bulk lyophilisate . )
Example 1.9. : Preparation of docetaxel/acetyl- γ - cyclodextrin/glucose co-lyophilisate 8 mg of docetaxel dissolved in 0.4 ml of ethanol are added to 400 mg of amorphised acetyl- γ -cyclodextrin. The wet powder is then dissolved in 8 ml of a 5% w/v aqueous glucose solution. This results in a clear solution with 1 mg/ml nominal docetaxel concentration which is frozen m dry-ice and freeze-dπed, to give a white lyophilisate with 1% docetaxel content.
100 mg of ethanol free solid lyophilisate can easily be reconstituted in 1, 2 or 4 ml of distilled water giving clear solutions of 1, 0.5 or 0.25 mg/ml nominal docetaxel concentrations, respectively. In Table 6. physical stability of do- cetaxel solutions during 21 hours of storage at room temperature in closed glass containers are summarised by determination of the dissolved docetaxel concentration by HPLC at different nominal concentrations.
TABLE 6
Dissolved docetaxel mg/ml HPLC Nominal dissolved docetaxel concentration
1 0 5 0 25 mg/ml mg/ml mg/ml at preparation 0 93 0 49 0 24 after 21 hours 0 89 0 48 0 24
Example I.10.: Preparation of binary do- cetaxel/hydroxypropyl-β-cyclodextπn (HPβCD) co-lyophilisate . 6 mg of docetaxel dissolved in 0.3 ml of ethanol are added to 300 mg of HPβCD. The wet powder is dissolved m 6 ml of distilled water resulting m a clear solution with 1 mg/ml nominal docetaxel concentration. This solution is frozen quickly in dry-ice and freeze dried, to obtain a white lyophilisate with 2_ w/w docetaxel content. 50 mg of the solid lyophilisate can easily be dissolved in 1 or 2 ml of a 5% w/v aqueous glucose solutions giving a clear solution of 0.97 and 0.59 mg/ml docetaxel content respectively, as determined by HPLC.
The reconstituted solutions are stored at room tempera- ture under normal conditions in glass containers. After 21 hours of storage 0.95 ± 0.05 and 0.49 ± 0.005 mg/ml docetaxel concentrations are assayed by HPLC.
Example I.11: Prolongation of the oversaturated dissolved state of the paclitaxel by way of co-evaporation 30 mg of Paclitaxel are dissolved in 6 ml of ethanol and the solution is mixed thoroughly with 5 g of acetyl- γ - cyclodextrin. Additional 3 ml of ethanol are added and the mixture is stirred for 5 minutes at room temperature. The ethanol content of the mixture is then removed in nitrogen stream using a rotatory evaporator in vacuum. The resulting white solid is then dissolved in 5 ml of deionised water resulting in a slightly opalescent solution that is immediately frozen with dry-ice and freeze-dried. The resulting lyophilisate is an instantly soluble amorphous powder. This is conven- iently reconstituted to a clear solution by adding injectable water or a 5% aqueous glucose solution. The reconstituted solution with 0.3 - 0.6 mg/ml dissolved paclitaxel concentration remains stable for at least 24 hours at room temperature. Example 1.12: Parenteral composition for intravenous use 100 mg of paclitaxel dissolved in 10 ml of ethanol are added to 15.0 g of amorphised large surface area acetyl- γ- cyclodextrin. To the wet powder further 10 ml of ethanol are added and the powder is dissolved in 80 ml of distilled water resulting in a clear solution with 1.25 mg/ml nominal pacli- taxel concentration. This solution is frozen quickly in dry- ice and freeze-dried to yield a white lyophilisate with 0.7 ± 0.05 %w paclitaxel content.
This lyophilisate can easily be reconstituted to 100 ml using a 5% w/v aqueous dextrose solution. A clear solution with 1.0 mg/ml paclitaxel concentration is obtained ready to use for intravenous application.
II. BIOLOGICAL STUDIES
The aim of the studies was to evaluate some specific side effects of intravenous administration of paclitaxel. Cardiovascular and respiratory effects of paclitaxel following intravenous administration were examined on a total of 7 beagle dogs maintained under α-chloralose/sodium pentobarbitone anaesthesia. II.1. TEST SUBSTANCES
A. Paclitaxel 1 ml liquid (30 mg/ml m ethanol) supplied m vials. Dissolved in vehicle Cremophor ELP : ethanol 1:1 on the course of the test.
B. Paclitaxel/AcγCD white crystalline powder; prepared ac- cording to Example I. 1.6. of the present patent specification. Dissolved in vehicle 2.5% w/v aqueous dextrose on the course of the test.
II.2. METHODS The following parameters were recorded or derived and served as indicators of the functional status of the various elements within the cardiovascular and respiratory systems. The units of measurement are stated in parenthesis.
Systolic, diastolic, mean blood pressure General haemodynamic status
(mmHg) Heart rate (beats/minute)
Left ventricular systolic pressure (mmHg) Contractile status of the myocardium Left ventricular dp/dt max (mmHg sec ')
Electrodiagram (lead H) Electrical status of the myocardium
Femoral flow (ml/minute) Status and resistance of the peripheral
Femoral resistance (mmHg/ml/minute) vasculature
Respiration rate (breaths/minute) General respiratory status
Respiration minute volume (ml) Respiration tidal volume (ml)
Anaesthesia was induced by I.V. injection of sodium thio- pentone and maintained i.v. by a mixture of -chloralose and pentobarbitone sodium given as required. Body temperature was maintained.
The trachea was cannulated and the canule connected to a pneumotach screen to allow measurement of tidal volume (ml) and the derived parameters of respiration rate (br/min) and minute volume (ml) . Catheters were introduced into the right femoral artery and a cephalic vein to facilitate measurements of blood pressure and the administration of vehicle, test sub- stances and anaesthetic respectively. The femoral artery was connected to a hepar /salme filled pressure transducer, coupled to a Grass 7E polygraph. Heart rate was derived elec- tronically from the blood pressure signal.
An ultrasonic flow probe was positioned around the left femoral artery and connected to a blood flow meter coupled to the Grass polygraph to record femoral blood flow (ml/mm) .
A catheter was introduced into the left carotid artery and advanced into the left ventricle to facilitate the measurement of the left ventricular systolic pressure (LVSP) . The catheter was connected to a heparm/salme-filled pressure transducer and the LVSP signal was displayed on the Grass polygraph.
Subcutaneous needle electrodes were inserted in the appropriate limbs m order to monitor the electrocardiogram which was displayed on the Grass polygraph. Various signals were transferred from the Grass polygraph to a computer and the captured data were analysed and displayed.
Following a 30 minute stabilization period, the vehicle was administered i.v. at a dose volume of 7.0 ml/kG over a pe- nod of 15 minutes. 45 minutes later and a minimum of 45 minutes intervals thereafter doses of the drugs were administered i.v. at a dose volume of 7.0 ml/kG again over 15 minutes each. The parameters were monitored for a least 45 minutes from the start of infusion. All doses were administered using a KdS model 200 infusion pump.
Following samples were tested:
N° Animal Vehicle l v Drug Drug Dose
7 ml/kG, 15 min mg/m2 1 Cremophor ELP ethanol paclitaxel 6, 60
2 Cremophor ELP ethanol paclitaxel 6, 60
3 2901AK Cremophor ELP ethanol none
4 2841AK Cremophor ELP ethanol none
5 D2515 2 5% dextrose/ in water pac taxel/AcγCD* 10, 20, 40, 60 6 6 D D22993377 2 5% dextrose/ in water pac taxel/AcγCD* 40, 10, 60, 90
7 D5 2 5% dextrose/ in water pachtaxel/AcγCD* 90, 120, 240
*= prepared according to Example 1.6.
All parameters including high resolution (50 mm/sec) recordings of the ECG were measured at 5 minute intervals during the stabilization period and at 0.5, 1, 2 and 5 minutes inter- vals post-dose following vehicle and drug administration. At the end of the full observation period the animals were killed with and overdose of pentobarbitone sodium, i.v.
II.3. RESULTS
Animals Results
1 and 2 Administration of 6 and 60 mg/m2 paclitaxel in Cremophor ELP : ethanol 1:1 was discontinued because of death of the animals. 3 and 4 Intravenous administration of Cremophor ELP : ethanol at both dose levels (corresponding to the doses used with 6 and 60 mg/m2 paclitaxel respectively) induced an anaphylactic type response: immediate decrease in arterial blood pressure, heart rate, left ventricular systolic pressure and left ventricular dp/dt maximum of similar magnitude in both animals. Little or no recovery in any cardiovascular parameter was observed post-dose. Both doses levels induced ventricular ec- topic beats, reduced the overall amplitude of the ECG wave-form, caused notching of the T-wave and reduction in T-wave amplitude. In animal 2841AK the vehicle also induced elevation of the S-T segment.
As a results of these finding it may be concluded that the solvent-mixture per se is toxic and should be avoided in i.v. administration.
5; 6; 7 Administration of 2.5% w/v of dextrose at a dose volume of 7 ml/kG induced no overall overt effects on any of the cardiovascular or respiratory parameters in the 3 animals tested. Addition of the paclitaxel/AcγCD doses up to 240 mg/m2 in general caused only small changes in the measured cardiovascular and respiratory parameters. Slight effects included slight increases in arterial blood pressure and left ventricular systolic pressure, accompanied by decreases in heart rate and left ventricular dp/dt maximum. Other inconsistent changes included increases in femoral flow, tidal volume and respiration rate. The findings were reversible.
11.4. FIGURES To illustrate an important parameter of the results the effect on arterial blood pressure following i.v. administration in the anaesthetised beagle dog is shown in Figures 1 to 6: Arterial blood pressure (mmHg) versus time (minutes):
-•—•—•— systolic —A—A—A— diastolic
Graph animal vehicle drug mg/m2
Figure 1 2901AK Cremophor : ethanol none Figure 2 2841AK Cremophor : ethanol none Figure 3 D2515 2.5% dextrose in water paclitaxel/AcγCD Ex. I. 6.
10, 20, 40, 60
Figure 4 D5 2.5% dextrose in water paclitaxel/AcγCD Ex. I. 6.
120, 90, 240
Figure 5 D2937 2.5% dextrose in water paclitaxel/ AcγCD Ex. 1 .6
10, 90; 40; 60
Figure 6 D5 2.5% dextrose in water paclitaxel/AcγCD Ex. I. 6 mean 120; 90; 240 pressure
I I . 5 . SUMMARY : Intravenous administration of the Cremophor ELP : ethanol
1:1 vehicle as well as paclitaxel along with this vehicle caused an anaphylactic type reaction and is thus inadequate to be administered. Administration of paclitaxel/acetyl-γ-CD
(from 20 mg up to 240 mg/m2) in aqueous dextrose as vehicle failed to produce marked and persistent cardiovascular overt effects on any of the parameters in any of the animals tested.

Claims

1. Process for the preparation of pharmaceutical compositions in instantly soluble solid state and its solutions in aqueous solvents for parenteral use containing acetyl- ╬│-cyclodextrin or hydroxy-propyl-╬▓-cyclodextrin (in the following cyclodextrin ) characterized by a) dissolving in ethanol a taxoid preferably paclitaxel or docetaxel, or a salt or hydrate or solvate thereof and thereafter performing either of the fol- lowing steps: i) adding solid cyclodextrin (and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes), dissolving the mixture in an aqueous solvent and lyophilising to obtain a solid; or ii) adding lyophilised cyclodextrin (and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes) , evaporating the solvent and drying to obtain a solid; or iii) admixing the solution with solid large surface area preferably lyophilised cyclodextrin, optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes and thereafter dissolving with an aqueous solvent optionally in the presence of an isotonizing additive to obtain a solution; containing
A. as an active ingredient the said taxoid and B. the said cyclodextrin and
C. optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes whereby the weight ratio of taxoid : cyclodextrin ranges between 1 : 25 and 1 : 400; and optionally b) when steps i) or ii) were used dissolving the solid in an aqueous solvent to obtain a parenteral solution ready for direct medical treatment .
2. The process according to claim 1 characterized by using as the aqueous solvent or diluent any of the following: water of injectable quality, an aqueous solution of isotonizing additive such as sodium chloride, glucose or dextrose containing these ingredients in an effective amount to isotonize the aqueous solution.
3. The process according to any of claims 1 and 2 characterized by using as the cyclodextrin component any of the following: acetyl- ╬│-cyclodextrin having a degree of acetylation between about 2 to about 12 acetyl groups per cyclodextrin ring, acetyl- ╬│-cyclodextrin having a de- gree of acetylation of about 8 acetyl groups per cyclodextrin ring.
4. The process according to any of claims 1 and 2 char- acterized by using as the cyclodextrin component any of the following: hydroxy-propyl-╬▓-cyclodextrin having a degree of substitution between about 2 to about 10 hydroxypropyl groups per cyclodextrin ring, hydroxy-propyl- ╬▓-cyclodextrin having a degree of substitution between about 4 to about 6 hydroxypropyl groups per cyclodextrin ring.
5. The process according to any of claims 1 to 4 characterized by using paclitaxel in its hydrated poly- morphic form or in its solvated form such as the ethanol solvate .
6. Water-soluble solid pharmaceutical compositions and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a finely dispersed large surface area amorphous preferably lyophilized taxoid such as paclitaxel or docetaxel, their salts or their polymorphic hydrates or solvates such as solvates formed with ethanol and b) finely dispersed large surface area amorphous preferably lyophilized acetyl- ╬│-cyclodextrin or hydroxy-propyl-╬▓-cyclodextrin (cyclodextrin) whereby the weight ratio of said taxoid : said cyclodextrin ranges between 1 : 25 and 1 : 400 c) and optionally other water-soluble auxiliary materials usual in pharmaceuticals for parenteral purposes .
A composition according to claim 5 characterized b y containing as the active ingredient paclitaxel and acetyl- ╬│ -cyclodextrin in a 1 : 100 to 1 : 250 weight ratio .
A composition according to claim 5 characterized b y containing as the active ingredient docetaxel and hydroxy-propyl-╬▓-cyclodextrin in a 1 : 25 to 1 : 100 weight ratio.
Pharmaceutical compositions containing as active ingredients any of the products prepared according to claims 1 to 4 .
10. A method for prevention of self-aggregation and premature precipitation of a taxoid of the group paclitaxel and docetaxel and their salts, solvates and hydrates in aqueous solutions and to prolongate the oversaturated dissolved state of the drug by using the taxoids in the form of pharmaceutical compositions according to any of claims 5 to 8.
11. Method of treatment of unwanted cell proliferation by utilising effective amounts of pharmaceutical compositions according to any of claims 1 to 8 characterized by administering to a patient in need of such treatment a dosage form containing the pharmaceutical composition according to any of claims 1 to 8 containing an effective amount of a taxoid preferably of the group paclitaxel and docetaxel and their salts and solvates and hydrates .
PCT/HU1998/000097 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids WO1999024073A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR9814015-9A BR9814015A (en) 1997-11-10 1998-11-09 Process for the preparation of instantly soluble solid products for pharmaceutical use, said products, method of prevention and treatment
DE69839224T DE69839224T2 (en) 1997-11-10 1998-11-09 PHARMACEUTICAL COMPOSITION CONTAINING CYCLODEXTRINS AND TAXOIDS
JP2000520158A JP3656550B2 (en) 1997-11-10 1998-11-09 Pharmaceutical composition containing cyclodextrin and taxoid
KR1020007005076A KR100607391B1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
IL13599098A IL135990A0 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
EA200000494A EA002776B1 (en) 1997-11-10 1998-11-09 Pharmaceutical composition containing cyclodextrins and taxoids
EP98955818A EP1059942B1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
CA2309326A CA2309326C (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
NZ504098A NZ504098A (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
AU12538/99A AU742036B2 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
NO20002165A NO329382B1 (en) 1997-11-10 2000-04-27 Process for the preparation of immediately soluble solid products, the product itself and its use and methods for the prevention of self-aggregation and premature precipitation of a taxoid
US11/542,797 US7671042B2 (en) 1997-11-10 2006-10-04 Pharmaceutical compositions containing cyclodextrins and taxoids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids
HUP9701945 1997-11-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09554064 A-371-Of-International 1998-11-09
US11/542,797 Continuation US7671042B2 (en) 1997-11-10 2006-10-04 Pharmaceutical compositions containing cyclodextrins and taxoids

Publications (2)

Publication Number Publication Date
WO1999024073A1 true WO1999024073A1 (en) 1999-05-20
WO1999024073B1 WO1999024073B1 (en) 1999-07-08

Family

ID=89995733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1998/000097 WO1999024073A1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids

Country Status (19)

Country Link
US (1) US7671042B2 (en)
EP (1) EP1059942B1 (en)
JP (1) JP3656550B2 (en)
KR (1) KR100607391B1 (en)
CN (1) CN1222321C (en)
AR (1) AR015482A1 (en)
AT (1) ATE387916T1 (en)
AU (1) AU742036B2 (en)
BR (1) BR9814015A (en)
CA (1) CA2309326C (en)
DE (1) DE69839224T2 (en)
EA (1) EA002776B1 (en)
HU (1) HUP9701945A3 (en)
IL (1) IL135990A0 (en)
NO (1) NO329382B1 (en)
NZ (1) NZ504098A (en)
PL (1) PL199652B1 (en)
WO (1) WO1999024073A1 (en)
ZA (1) ZA989779B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
EP1543841A1 (en) * 2002-08-15 2005-06-22 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
US6989381B2 (en) 2000-08-22 2006-01-24 Pharmacia Corporation Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
WO2007082978A1 (en) 2006-01-20 2007-07-26 Eriochem S.A. Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation
WO2007136219A1 (en) * 2006-05-22 2007-11-29 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
WO2008031285A1 (en) 2006-09-12 2008-03-20 Nanjing Normal University Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
WO2009043956A1 (en) 2007-10-03 2009-04-09 Capital, Business Y Gestión De Finanzas, S.L Taxane pharmaceutical formulation
WO2009066956A2 (en) * 2007-11-22 2009-05-28 Sk Chemicals Co., Ltd. Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
EP2146695A2 (en) * 2007-04-23 2010-01-27 Sun Pharmaceuticals Industries Ltd. Pharmaceutical compositions
EP2170319A2 (en) * 2007-06-22 2010-04-07 Scidose, Llc Solubilized formulation of docetaxel without tween 80
KR100983377B1 (en) * 2006-06-02 2010-09-20 에스케이케미칼주식회사 Method for preparing a stable pharmaceutical composition containing paclitaxel
US20110028457A1 (en) * 2008-04-04 2011-02-03 Norbert Roewer Pharmaceutical preparation comprising permethylated cyclodextrin
US8426385B2 (en) 2006-09-12 2013-04-23 Hainan Hdeton Science And Technology Co. Ltd. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
US8802095B2 (en) 2007-01-26 2014-08-12 Durect Corporation Injectable, non-aqueous suspension with high concentration of therapeutic agent
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
WO2018056720A1 (en) * 2016-09-21 2018-03-29 씨제이헬스케어 주식회사 Injectable composition having enhanced stability
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
WO2019009661A1 (en) 2017-07-07 2019-01-10 Cj Healthcare Corporation Composition for injection
WO2020019363A1 (en) 2018-07-25 2020-01-30 比卡生物科技（广州）有限公司 Docetaxel composition for injection and preparation method therefor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384865C (en) * 2001-11-02 2008-04-30 嵌入治疗公司 Methods and composition for therapeutic use of RNA interference
CN101020059B (en) * 2006-02-15 2011-01-05 中国科学院上海药物研究所 Medicine composition containing docetaxel matter and its preparation process
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
KR101502533B1 (en) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 Stable pharmaceutical composition containing Taxane derivatives, and method of manufacturing the same
KR20120130740A (en) * 2011-05-23 2012-12-03 에스케이케미칼주식회사 Liquid composition for injection of docetaxel
US11406595B2 (en) * 2012-05-21 2022-08-09 University Of Maryland, College Park Highly stable colloid from aqueous solutions of small organic molecules
CN105823810A (en) * 2016-01-04 2016-08-03 杭州电子科技大学 Detection apparatus and detection method for chemotherapy effect of paclitaxel
WO2022250469A1 (en) * 2021-05-26 2022-12-01 주식회사 대웅제약 Novel injectable formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN115960834B (en) * 2023-03-07 2023-06-09 浙江省肿瘤医院 PD-1/PTX combined PD-1 drug resistance model establishment method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605753A1 (en) * 1992-11-27 1994-07-13 Ensuiko Sugar Refining Company, Limited Cyclodextrin inclusion complex of taxol, and method for its production and its use
WO1994026728A1 (en) * 1993-05-12 1994-11-24 Chinoin Ltd. Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, its preparation and use
EP0639380A1 (en) * 1993-08-19 1995-02-22 Ensuiko Sugar Refining Company, Limited Cyclodextrin inclusion product of taxol, process for producing the same, and its use
WO1995006485A1 (en) * 1993-09-03 1995-03-09 Supergen, Inc. Improved pharmaceutical formulation
EP0680975A1 (en) * 1994-04-22 1995-11-08 Consortium für elektrochemische Industrie GmbH Acylated gamma-cyclodextrins
WO1996014872A1 (en) * 1994-11-11 1996-05-23 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Novel complexes and their compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163837C (en) * 1994-12-13 1999-07-20 Robert K. Perrone Crystalline paclitaxel hydrates
CN1596250A (en) * 2001-11-30 2005-03-16 布里斯托尔-迈尔斯斯奎布公司 Paclitaxel solvates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605753A1 (en) * 1992-11-27 1994-07-13 Ensuiko Sugar Refining Company, Limited Cyclodextrin inclusion complex of taxol, and method for its production and its use
WO1994026728A1 (en) * 1993-05-12 1994-11-24 Chinoin Ltd. Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, its preparation and use
EP0639380A1 (en) * 1993-08-19 1995-02-22 Ensuiko Sugar Refining Company, Limited Cyclodextrin inclusion product of taxol, process for producing the same, and its use
WO1995006485A1 (en) * 1993-09-03 1995-03-09 Supergen, Inc. Improved pharmaceutical formulation
EP0680975A1 (en) * 1994-04-22 1995-11-08 Consortium für elektrochemische Industrie GmbH Acylated gamma-cyclodextrins
WO1996014872A1 (en) * 1994-11-11 1996-05-23 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Novel complexes and their compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DORDUNOO, STEPHEN K. ET AL: "Solubility and stability of taxol: effects of buffers and cyclodextrins", INT. J. PHARM. (1996), 133(1,2), 191-201 CODEN: IJPHDE;ISSN: 0378-5173, XP002091507 *
SHARMA U S ET AL: "PHARMACEUTICAL AND PHYSICAL PROPERTIES OF PACLITAXEL (TAXOL) COMPLEXES WITH CYCLODEXTRINS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 84, no. 10, 1 October 1995 (1995-10-01), pages 1223 - 1230, XP000529731 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989381B2 (en) 2000-08-22 2006-01-24 Pharmacia Corporation Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
EP1543841A1 (en) * 2002-08-15 2005-06-22 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
EP1543841A4 (en) * 2002-08-15 2011-03-16 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
WO2007082978A1 (en) 2006-01-20 2007-07-26 Eriochem S.A. Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation
WO2007136219A1 (en) * 2006-05-22 2007-11-29 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
AU2007252371B2 (en) * 2006-05-22 2013-07-25 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
EA014071B1 (en) * 2006-05-22 2010-08-30 Ск Кемикалз Ко., Лтд. Stable pharmaceutical composition containing docetaxel and method of preparing same
US8791152B2 (en) 2006-05-22 2014-07-29 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
KR100983377B1 (en) * 2006-06-02 2010-09-20 에스케이케미칼주식회사 Method for preparing a stable pharmaceutical composition containing paclitaxel
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
CN100411688C (en) * 2006-09-12 2008-08-20 南京师范大学 Medicine composition containing cyclodextrin/polyene taxol and its prepn process
WO2008031285A1 (en) 2006-09-12 2008-03-20 Nanjing Normal University Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US8426385B2 (en) 2006-09-12 2013-04-23 Hainan Hdeton Science And Technology Co. Ltd. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
US8481511B2 (en) 2006-09-12 2013-07-09 Hainan Hdeton Science and Technology Co., Ltd. Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US8802095B2 (en) 2007-01-26 2014-08-12 Durect Corporation Injectable, non-aqueous suspension with high concentration of therapeutic agent
EP2146695A2 (en) * 2007-04-23 2010-01-27 Sun Pharmaceuticals Industries Ltd. Pharmaceutical compositions
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd Pharmaceutical compositions
EP2170319A2 (en) * 2007-06-22 2010-04-07 Scidose, Llc Solubilized formulation of docetaxel without tween 80
EP2170319A4 (en) * 2007-06-22 2011-10-12 Scidose Llc Solubilized formulation of docetaxel without tween 80
WO2009043956A1 (en) 2007-10-03 2009-04-09 Capital, Business Y Gestión De Finanzas, S.L Taxane pharmaceutical formulation
WO2009066956A2 (en) * 2007-11-22 2009-05-28 Sk Chemicals Co., Ltd. Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
WO2009066956A3 (en) * 2007-11-22 2009-07-16 Sk Chemicals Co Ltd Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
CN101868232B (en) * 2007-11-22 2013-02-13 Sk化学株式会社 Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
EP2219640A4 (en) * 2007-11-22 2013-09-25 Sk Chemicals Co Ltd Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
EP2219640A2 (en) * 2007-11-22 2010-08-25 SK Chemicals, Co., Ltd. Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
US8980882B2 (en) * 2008-04-04 2015-03-17 Norbert Roewer Pharmaceutical preparation comprising permethylated cyclodextrin
US20110028457A1 (en) * 2008-04-04 2011-02-03 Norbert Roewer Pharmaceutical preparation comprising permethylated cyclodextrin
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
WO2018056720A1 (en) * 2016-09-21 2018-03-29 씨제이헬스케어 주식회사 Injectable composition having enhanced stability
WO2019009661A1 (en) 2017-07-07 2019-01-10 Cj Healthcare Corporation Composition for injection
KR20190005674A (en) 2017-07-07 2019-01-16 씨제이헬스케어 주식회사 Composition for injection
US10828253B2 (en) 2017-07-07 2020-11-10 Hk Inno.N Corporation Composition for injection
WO2020019363A1 (en) 2018-07-25 2020-01-30 比卡生物科技（广州）有限公司 Docetaxel composition for injection and preparation method therefor

Also Published As

Publication number Publication date
NZ504098A (en) 2003-06-30
HUP9701945A1 (en) 1999-09-28
US20070087999A1 (en) 2007-04-19
NO20002165L (en) 2000-07-07
CA2309326C (en) 2010-12-21
HUP9701945A3 (en) 2000-04-28
PL199652B1 (en) 2008-10-31
WO1999024073B1 (en) 1999-07-08
EA200000494A1 (en) 2000-10-30
CN1281373A (en) 2001-01-24
EP1059942A2 (en) 2000-12-20
ATE387916T1 (en) 2008-03-15
CN1222321C (en) 2005-10-12
EP1059942B1 (en) 2008-03-05
CA2309326A1 (en) 1999-05-20
DE69839224T2 (en) 2009-04-16
DE69839224D1 (en) 2008-04-17
KR20010031967A (en) 2001-04-16
US7671042B2 (en) 2010-03-02
NO20002165D0 (en) 2000-04-27
AR015482A1 (en) 2001-05-02
EA002776B1 (en) 2002-08-29
BR9814015A (en) 2000-09-26
ZA989779B (en) 1999-04-28
AU742036B2 (en) 2001-12-13
PL340505A1 (en) 2001-02-12
JP3656550B2 (en) 2005-06-08
AU1253899A (en) 1999-05-31
JP2001522816A (en) 2001-11-20
KR100607391B1 (en) 2006-08-02
NO329382B1 (en) 2010-10-04
IL135990A0 (en) 2001-05-20
HU9701945D0 (en) 1998-01-28

Similar Documents

Publication Publication Date Title
US7671042B2 (en) Pharmaceutical compositions containing cyclodextrins and taxoids
FI92556C (en) A method of preparing an intravenous pharmaceutical composition
JP5587198B2 (en) Freeze-dried pharmaceutical composition having improved stability, containing taxane derivative, and method for producing the same
US20120316146A1 (en) Anaesthetic formulation
CA2748761C (en) Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
EP3556349B1 (en) Parenteral liquid preparation comprising carbamate compound
US8293749B2 (en) Injectable meclizine formulations and methods
EP2649035A1 (en) A complex of garcinol, cyclodextrin and method thereof
CN109223769B (en) Nanoparticles with synergistic and toxicity-reducing effects on annonaceous acetogenins, and preparation method and application thereof
CZ20001636A3 (en) Pharmaceutical preparations containing cyclodextrins and taxoids
JPH0429924A (en) Injection preparation containing fat-soluble drug
JPH07316065A (en) Pharmaceutical preparation of fr 901469 substance
Wray-Cahen et al. Methyl-β-cyclodextrin: an alternative carrier for intravenous infusion of palmitate during tracer studies in swine (Sus scrofa domestica)
CN114732789A (en) Compound long-acting drug delivery system for treating pulmonary hypertension and preparation thereof
JP2008509141A (en) Methods and compositions for reducing tissue irritation in parenteral formulations
JP2005520856A (en) Eplerenone formulation stable during storage

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135990

Country of ref document: IL

Ref document number: 98811010.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BG BR CA CN CU CZ EE GE HR ID IL IS JP KP KR LR LT LV MK MN MX NO NZ PL RO SI SK TR UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AU BA BG BR CA CN CU CZ EE GE HR ID IL IS JP KP KR LR LT LV MK MN MX NO NZ PL RO SI SK TR UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 504098

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2000-1636

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2309326

Country of ref document: CA

Ref document number: 2309326

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12538/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004456

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020007005076

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998955818

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200000494

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09554064

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2000-1636

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998955818

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007005076

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 12538/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007005076

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998955818

Country of ref document: EP